Neumora Therapeutics (NMRA) Competitors $1.86 -0.03 (-1.59%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.34%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. PRAX, NUVB, COLL, WVE, ORIC, TRVI, PGEN, IMNM, CRON, and BGMShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Praxis Precision Medicines (PRAX), Nuvation Bio (NUVB), Collegium Pharmaceutical (COLL), WAVE Life Sciences (WVE), Oric Pharmaceuticals (ORIC), Trevi Therapeutics (TRVI), Precigen (PGEN), Immunome (IMNM), Cronos Group (CRON), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Praxis Precision Medicines Nuvation Bio Collegium Pharmaceutical WAVE Life Sciences Oric Pharmaceuticals Trevi Therapeutics Precigen Immunome Cronos Group BGM Group Praxis Precision Medicines (NASDAQ:PRAX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends. Is PRAX or NMRA more profitable? Praxis Precision Medicines' return on equity of -60.07% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision MedicinesN/A -60.07% -54.84% Neumora Therapeutics N/A -98.95%-87.68% Does the media favor PRAX or NMRA? In the previous week, Neumora Therapeutics had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 3 mentions for Neumora Therapeutics and 2 mentions for Praxis Precision Medicines. Neumora Therapeutics' average media sentiment score of 0.99 beat Praxis Precision Medicines' score of 0.34 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, PRAX or NMRA? Praxis Precision Medicines has higher revenue and earnings than Neumora Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M128.12-$182.82M-$12.29-4.23Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.18 Do institutionals and insiders believe in PRAX or NMRA? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate PRAX or NMRA? Praxis Precision Medicines presently has a consensus price target of $85.56, suggesting a potential upside of 64.40%. Neumora Therapeutics has a consensus price target of $7.14, suggesting a potential upside of 284.02%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75Neumora Therapeutics 3 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, PRAX or NMRA? Praxis Precision Medicines has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. SummaryPraxis Precision Medicines beats Neumora Therapeutics on 8 of the 14 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$306.08M$3.32B$6.10B$10.52BDividend YieldN/A2.29%5.51%4.70%P/E RatioN/A21.5485.6826.85Price / SalesN/A428.34585.01185.67Price / CashN/A46.3226.3031.10Price / Book1.0410.0613.256.72Net Income-$243.79M-$52.22M$3.30B$276.44M7 Day Performance2.20%5.84%4.70%3.13%1 Month Performance10.71%12.05%8.43%10.21%1 Year Performance-87.23%26.13%88.01%40.35% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.4375 of 5 stars$1.86-1.6%$7.14+284.0%-87.2%$306.08MN/A0.00108PRAXPraxis Precision Medicines2.2358 of 5 stars$52.38-0.1%$85.56+63.3%-21.5%$1.10B$8.55M-4.26110NUVBNuvation Bio2.902 of 5 stars$3.22+0.6%$7.50+132.9%+56.4%$1.10B$7.87M-5.1160Gap UpCOLLCollegium Pharmaceutical4.1568 of 5 stars$34.57+0.5%$42.33+22.5%-19.2%$1.08B$631.45M33.24210Positive NewsWVEWAVE Life Sciences4.4848 of 5 stars$7.13+4.9%$20.33+185.2%-14.1%$1.08B$108.30M-7.92240ORICOric Pharmaceuticals4.2034 of 5 stars$11.62+4.5%$17.29+48.8%+49.9%$1.08BN/A-6.1580News CoverageGap UpTRVITrevi Therapeutics2.5128 of 5 stars$8.95+2.1%$21.75+143.0%+229.5%$1.07BN/A-21.3120PGENPrecigen4.5475 of 5 stars$3.63+3.4%$8.25+127.3%+248.9%$1.05B$3.92M-8.64190IMNMImmunome1.4423 of 5 stars$11.34-2.2%$23.20+104.6%+9.4%$1.01B$9.04M-3.6840CRONCronos Group1.4762 of 5 stars$2.97+12.9%N/A+13.8%$1.01B$117.61M59.40450Gap UpHigh Trading VolumeBGMBGM Group0.2534 of 5 stars$9.61-5.4%N/A+28.5%$987.78M$25.10M0.00298Positive NewsGap Down Related Companies and Tools Related Companies Praxis Precision Medicines Competitors Nuvation Bio Competitors Collegium Pharmaceutical Competitors WAVE Life Sciences Competitors Oric Pharmaceuticals Competitors Trevi Therapeutics Competitors Precigen Competitors Immunome Competitors Cronos Group Competitors BGM Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
